106.38
price up icon0.82%   0.87
after-market After Hours: 106.57 0.19 +0.18%
loading
Gilead Sciences Inc stock is traded at $106.38, with a volume of 7.77M. It is up +0.82% in the last 24 hours and down -0.65% over the past month. Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$105.51
Open:
$105.95
24h Volume:
7.77M
Relative Volume:
0.91
Market Cap:
$130.75B
Revenue:
$28.75B
Net Income/Loss:
$480.00M
P/E Ratio:
287.51
EPS:
0.37
Net Cash Flow:
$10.31B
1W Performance:
+1.43%
1M Performance:
-0.65%
6M Performance:
+21.95%
1Y Performance:
+58.71%
1-Day Range:
Value
$99.32
$106.64
1-Week Range:
Value
$99.32
$106.64
52-Week Range:
Value
$62.07
$119.96

Gilead Sciences Inc Stock (GILD) Company Profile

Name
Name
Gilead Sciences Inc
Name
Phone
(650) 574-3000
Name
Address
333 LAKESIDE DR, FOSTER CITY, CA
Name
Employee
17,600
Name
Twitter
@GileadSciences
Name
Next Earnings Date
2025-02-11
Name
Latest SEC Filings
Name
GILD's Discussions on Twitter

Compare GILD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
GILD
Gilead Sciences Inc
106.38 130.75B 28.75B 480.00M 10.31B 0.37
Drug Manufacturers - General icon
LLY
Lilly Eli Co
829.42 744.96B 45.04B 10.59B 414.30M 11.71
Drug Manufacturers - General icon
JNJ
Johnson Johnson
155.38 371.98B 89.33B 21.81B 18.06B 8.99
Drug Manufacturers - General icon
ABBV
Abbvie Inc
177.05 303.70B 56.33B 4.28B 17.83B 2.40
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
61.30 279.13B 42.09B 14.65B 10.11B 3.2833
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
110.13 216.43B 51.72B 11.94B 13.81B 5.88

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-22-25 Resumed Cantor Fitzgerald Overweight
Mar-04-25 Reiterated Oppenheimer Outperform
Feb-18-25 Upgrade Deutsche Bank Hold → Buy
Feb-13-25 Upgrade DZ Bank Hold → Buy
Jan-10-25 Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-10-24 Resumed BofA Securities Buy
Nov-15-24 Initiated Wolfe Research Outperform
Nov-14-24 Initiated Citigroup Buy
Nov-08-24 Downgrade Maxim Group Buy → Hold
Oct-21-24 Upgrade Leerink Partners Market Perform → Outperform
Oct-17-24 Initiated Bernstein Outperform
Oct-07-24 Upgrade Wells Fargo Equal Weight → Overweight
Jul-08-24 Upgrade Raymond James Mkt Perform → Outperform
May-01-24 Reiterated Maxim Group Buy
Apr-24-24 Upgrade HSBC Securities Reduce → Hold
Feb-22-24 Downgrade Truist Buy → Hold
Nov-09-23 Initiated Deutsche Bank Hold
Sep-08-23 Upgrade BofA Securities Neutral → Buy
Sep-06-23 Initiated HSBC Securities Reduce
Jul-24-23 Reiterated Barclays Equal Weight
May-16-23 Upgrade BMO Capital Markets Market Perform → Outperform
Apr-28-23 Resumed Piper Sandler Overweight
Jan-03-23 Downgrade RBC Capital Mkts Outperform → Sector Perform
Dec-13-22 Resumed BofA Securities Neutral
Dec-09-22 Downgrade DZ Bank Buy → Hold
Oct-31-22 Upgrade Barclays Underweight → Equal Weight
Oct-28-22 Reiterated BMO Capital Markets Market Perform
Oct-28-22 Reiterated Cowen Outperform
Oct-28-22 Reiterated JP Morgan Overweight
Oct-28-22 Reiterated Jefferies Buy
Oct-28-22 Upgrade Piper Sandler Neutral → Overweight
Oct-28-22 Reiterated RBC Capital Mkts Outperform
Oct-28-22 Upgrade Truist Hold → Buy
Oct-28-22 Reiterated Wells Fargo Equal Weight
Oct-04-22 Upgrade JP Morgan Neutral → Overweight
Jul-13-22 Initiated Cantor Fitzgerald Neutral
May-23-22 Initiated SVB Leerink Mkt Perform
Feb-28-22 Downgrade BMO Capital Markets Outperform → Market Perform
Feb-02-22 Reiterated BMO Capital Markets Outperform
Feb-02-22 Reiterated BofA Securities Neutral
Feb-02-22 Reiterated RBC Capital Mkts Outperform
Feb-02-22 Reiterated Truist Hold
Feb-02-22 Reiterated Wells Fargo Equal Weight
Jan-28-22 Upgrade Argus Hold → Buy
Jan-06-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-09-21 Resumed Wells Fargo Equal Weight
Dec-06-21 Initiated Goldman Neutral
Nov-19-21 Upgrade BMO Capital Markets Market Perform → Outperform
Nov-19-21 Resumed Piper Sandler Neutral
Oct-20-21 Resumed Cowen Outperform
Jul-30-21 Reiterated BMO Capital Markets Market Perform
Jul-30-21 Reiterated RBC Capital Mkts Outperform
Apr-01-21 Upgrade Bernstein Mkt Perform → Outperform
Mar-30-21 Upgrade Redburn Neutral → Buy
Jan-19-21 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-04-21 Upgrade Guggenheim Neutral → Buy
Nov-03-20 Resumed Morgan Stanley Equal-Weight
Oct-28-20 Initiated UBS Neutral
Sep-30-20 Resumed Jefferies Buy
Sep-15-20 Upgrade Maxim Group Hold → Buy
Jul-31-20 Reiterated Credit Suisse Neutral
Jul-31-20 Reiterated Morgan Stanley Equal-Weight
Jul-31-20 Reiterated Piper Sandler Overweight
Jul-31-20 Reiterated RBC Capital Mkts Outperform
Jul-31-20 Reiterated SunTrust Hold
Jul-31-20 Reiterated Wells Fargo Equal Weight
Jul-20-20 Upgrade Credit Suisse Underperform → Neutral
Jun-03-20 Upgrade SVB Leerink Mkt Perform → Outperform
May-26-20 Upgrade SunTrust Sell → Hold
May-01-20 Downgrade JP Morgan Overweight → Neutral
May-01-20 Downgrade Raymond James Outperform → Mkt Perform
May-01-20 Downgrade SunTrust Hold → Sell
Apr-27-20 Downgrade UBS Buy → Neutral
Apr-20-20 Downgrade BMO Capital Markets Outperform → Market Perform
Apr-20-20 Downgrade Wells Fargo Overweight → Equal Weight
Apr-17-20 Downgrade CFRA Hold → Sell
View All

Gilead Sciences Inc Stock (GILD) Latest News

pulisher
Apr 23, 2025

P/E Ratio Insights for Gilead Sciences - Benzinga

Apr 23, 2025
pulisher
Apr 23, 2025

As Trump administration battles DEI, Gilead highlights its efforts - The Business Journals

Apr 23, 2025
pulisher
Apr 23, 2025

Gilead Sciences's Options Frenzy: What You Need to Know - Benzinga

Apr 23, 2025
pulisher
Apr 23, 2025

Biomedical HIV Prevention Summit in Atlanta Is the Focus To Drive Meaningful Action With Gilead Sciences - CSRwire

Apr 23, 2025
pulisher
Apr 23, 2025

Gilead Sciences (GILD) Earnings Report Preview: Key Insights for Investors - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Gilead Sciences Q1 2025 Earnings Preview (GILD:NASDAQ) - Seeking Alpha

Apr 23, 2025
pulisher
Apr 23, 2025

Exploring Gilead Sciences's Earnings Expectations - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

In Europe, Gilead flags CAR T access challenges - The Pharma Letter

Apr 23, 2025
pulisher
Apr 23, 2025

The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi - Yahoo Finance

Apr 23, 2025
pulisher
Apr 23, 2025

Gilead Sciences (GILD) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance

Apr 23, 2025
pulisher
Apr 23, 2025

Promising Commercial Potential for Gilead’s Trodelvy Following Successful ASCENT-04 Trial - TipRanks

Apr 23, 2025
pulisher
Apr 23, 2025

Trodelvy plus Keytruda effective for aggressive breast cancer type: Gilead Sciences - Medical Dialogues

Apr 23, 2025
pulisher
Apr 22, 2025

GILEAD SCIENCES Earnings Preview: Recent $GILD Insider Trading, Hedge Fund Activity, and More - Nasdaq

Apr 22, 2025
pulisher
Apr 22, 2025

Gilead reports topline data from Phase III trial of Trodelvy combo therapy - Clinical Trials Arena

Apr 22, 2025
pulisher
Apr 22, 2025

Cantor initiates coverage of U.S. large-cap pharma stocks: Gilead, AbbVie at Buy - Baystreet.ca

Apr 22, 2025
pulisher
Apr 22, 2025

Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds? - Insider Monkey

Apr 22, 2025
pulisher
Apr 22, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 22, 2025
pulisher
Apr 22, 2025

Cantor Fitzgerald maintains Overweight on Gilead with $125 target By Investing.com - Investing.com India

Apr 22, 2025
pulisher
Apr 22, 2025

Gilead’s Trodelvy, With Keytruda, Slows Disease Progression in Triple-Negative Breast Cancer - BioSpace

Apr 22, 2025
pulisher
Apr 22, 2025

Cantor Fitzgerald raises Gilead stock target to $125, cites HIV drug - Investing.com

Apr 22, 2025
pulisher
Apr 22, 2025

Gilead Sciences (GILD) Upgraded by Cantor Fitzgerald with Positive Outlook | GILD Stock News - GuruFocus

Apr 22, 2025
pulisher
Apr 22, 2025

Gilead Sciences to propel healthcare innovation and cell therapy advancement in Abu Dhabi - BioSpectrum Asia

Apr 22, 2025
pulisher
Apr 21, 2025

Lobbying Update: $1,662,000 of GILEAD SCIENCES INC lobbying was just disclosed - Nasdaq

Apr 21, 2025
pulisher
Apr 21, 2025

Gilead says Trodelvy-Keytruda combo effective for aggressive breast cancer type - Reuters

Apr 21, 2025
pulisher
Apr 21, 2025

Press Release Service: Advanced Therapy Medicinal Products Global Strategic Business Report 2025, with Profiles of Bluebird Bio, Gilead Sciences, JCR Pharmaceuticals, Kolon TissueGene, MediPost, Organogenesis and moreResearchAndMarkets.com - CRISPR Medicine News

Apr 21, 2025
pulisher
Apr 21, 2025

11 Cheap NASDAQ Stocks to Buy According to Hedge Funds - Insider Monkey

Apr 21, 2025
pulisher
Apr 21, 2025

Gilead Set To Expand Trodelvy/Keytruda Into Frontline TNBC - insights.citeline.com

Apr 21, 2025
pulisher
Apr 21, 2025

Gilead Cancer Drug Combined With Merck's Drug Effective In Difficult To Treat Type Of Breast Cancer - Benzinga

Apr 21, 2025
pulisher
Apr 21, 2025

Gilead eyes earlier use of Trodelvy in TNBC as Phase III hits key goal - FirstWord Pharma

Apr 21, 2025
pulisher
Apr 21, 2025

Gilead Sciences (NasdaqGS:GILD) Reveals Promising Phase 3 Trial Results For Trodelvy In mTNBC - Yahoo Finance

Apr 21, 2025
pulisher
Apr 21, 2025

Gilead's Trodelvy-Keytruda proposal hits goal in first-line triple-negative breast cancer - Fierce Pharma

Apr 21, 2025
pulisher
Apr 21, 2025

Gilead Sciences (GILD) Surprises with Positive ASCENT-04 Results, Analyst Optimistic | GILD Stock News - GuruFocus

Apr 21, 2025
pulisher
Apr 21, 2025

Gilead Sciences (GILD) Reports Positive Phase 3 Results for Breast Cancer Treatment | GILD Stock News - GuruFocus

Apr 21, 2025
pulisher
Apr 21, 2025

Gilead's (GILD) Trodelvy Shows Promise in Breast Cancer Study - GuruFocus

Apr 21, 2025
pulisher
Apr 21, 2025

Gilead Says Trodelvy-Keytruda Combination Improved Progression-Free Survival in Breast Cancer Study - marketscreener.com

Apr 21, 2025
pulisher
Apr 21, 2025

Gilead Trodelvy + Merck Keytruda combo excels in first-line breast cancer - Seeking Alpha

Apr 21, 2025
pulisher
Apr 21, 2025

Gilead Sciences Reports Positive Data From Phase 3 ASCENT-04/KEYNOTE-D19 Study - Nasdaq

Apr 21, 2025
pulisher
Apr 21, 2025

Gilead says its therapy delayed growth of tumors in aggressive form of breast cancer - statnews.com

Apr 21, 2025
pulisher
Apr 21, 2025

Gilead Sciences (GILD); Trodelvy Plus Keytruda Demonstrates Statistically Significant and Clinically Meaningful Improvement in PFS in Patients With nTNBC - StreetInsider

Apr 21, 2025
pulisher
Apr 21, 2025

Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer - Business Wire

Apr 21, 2025
pulisher
Apr 21, 2025

Cancer Immunotherapy Market Is Booming So Rapidly 2025-2032 - openPR.com

Apr 21, 2025
pulisher
Apr 20, 2025

Analysts’ Top Healthcare Picks: Evolent Health (EVH), Gilead Sciences (GILD) - The Globe and Mail

Apr 20, 2025
pulisher
Apr 20, 2025

Gilead Sciences: Strong Financial Outlook and Strategic Positioning Justify Buy Rating - TipRanks

Apr 20, 2025
pulisher
Apr 20, 2025

4,126,119 Shares in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Bought by Gilead Sciences Inc. - MarketBeat

Apr 20, 2025
pulisher
Apr 19, 2025

Lobbying Update: $60,000 of GILEAD SCIENCES INC. lobbying was just disclosed - Nasdaq

Apr 19, 2025
pulisher
Apr 18, 2025

What Analyst Projections for Key Metrics Reveal About Gilead (GILD) Q1 Earnings - MSN

Apr 18, 2025
pulisher
Apr 18, 2025

Here's Why Gilead Sciences (GILD) is a Strong Value Stock - Yahoo Finance

Apr 18, 2025
pulisher
Apr 18, 2025

Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now? - MSN

Apr 18, 2025
pulisher
Apr 17, 2025

BMO Capital Adjusts Gilead Sciences Price Target to $120 From $115 - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

Leerink Partners Adjusts Price Target on Gilead Sciences to $105 From $104, Keeps Outperform Rating - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance

Apr 17, 2025

Gilead Sciences Inc Stock (GILD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general PFE
$22.39
price down icon 0.62%
drug_manufacturers_general SNY
$53.02
price up icon 2.26%
$277.90
price down icon 0.18%
drug_manufacturers_general MRK
$78.74
price down icon 0.29%
drug_manufacturers_general NVS
$110.13
price down icon 1.15%
Cap:     |  Volume (24h):